Startup profile: Ajaya Bio<\/p>\n
Founded by: Mohit Sachdeva, Ramesh Singh<\/p>\n
Year founded: 2024<\/p>\n
Headquarters: Philadelphia, PA<\/p>\n
Sector: Biotech<\/p>\n
Funding and valuation: \u00a0$1 million raised at an undisclosed valuation, according to PitchBook\u00a0<\/p>\n
Key ecosystem partners: Ben Franklin Technology Partners, BioAdvance Capital, BioLabs Philadelphia, HiveBio Accelerator<\/p>\n
After a decade of developing drugs for other companies, biotech founder Mohit Sachdeva is now building his own \u2014 aimed at a different way of treating autoimmune disease.<\/p>\n
His company, Ajaya Bio<\/a>, is developing a drug designed to destroy the inflammatory cells that cause autoimmune diseases, rather than just blocking them. It\u2019s an approach Sachdeva hopes will help the startup become one of Philadelphia\u2019s next major life sciences companies, in a region known for breakouts like Spark Therapeutics<\/a>, the cell and gene therapy company where he previously worked.<\/p>\n \u201cWe are trying to build something that will have a lasting effect on the city ecosystem.\u201d<\/p>\n Mohit Sachdeva, Ajaya Bio<\/p>\n \u201cWe are trying to build something that will have a lasting effect on the city ecosystem,\u201d Sachdeva told Technical.ly. \u201cThe city has a lot of talent, so we need to create those kinds of jobs.\u201d<\/p>\n Sachdeva bootstrapped Ajaya, eventually leaning on friends for cash to pull together early data that could be presented to institutional investors.\u00a0<\/p>\n Ajaya previously participated in the HiveBio accelerator<\/a> last year and raised $1 million from BioAdvance Capital and Ben Franklin Technology Partners<\/a> to support its preclinical studies.\u00a0<\/p>\n That early interest from institutional investors is expected to give the company traction when it raises its next round, Sachdeva said. The firm is now preparing to raise a Series A round to fund manufacturing, regulatory filings, a clinical trial, and an expansion beyond its four-person team, he said.\u00a0<\/p>\n \u201cOur strategy was to let our data speak,\u201d he said. \u201cThese investors saw value in what we are building.\u201d\u00a0<\/p>\n Developing longer-term treatment for autoimmune diseases<\/p>\n Typically, patients with autoimmune diseases take medication to block inflammatory cells, called pathogenic immune cells, and slow disease progression, he said.\u00a0<\/p>\n Ajaya Bio is trying to get rid of those cells. The company developed a bispecific antibody, a lab-made molecule that links two antibodies together so they can work at the same time. One of the antibodies finds the inflammatory cells and the other antibody recruits immune cells in the body to kill them.\u00a0<\/p>\n \u201cEvery time we go to some patient advocacy group or patient meetings, we realize the treatments are there,\u201d he said. \u201cThey\u2019re managing the diseases, but we\u2019re not getting actual cures.\u201d\u00a0<\/p>\n This method of treatment means that patients wouldn\u2019t have to take the drug for as long, because the cells are being destroyed, he said.\u00a0<\/p>\n The company\u2019s lead program is a treatment for rheumatoid arthritis, and the company is currently conducting preclinical animal studies. After that, the company will start manufacturing its drug and submit an investigational new drug application to the FDA to get approval for clinical trials.\u00a0<\/p>\n In the next five years, Sachdeva hopes the drug will be in patients\u2019 hands and that the company will continue to expand its products.\u00a0<\/p>\n \u201cWe also are developing a broader pipeline where we can target other autoimmune diseases using the same drug,\u201d Sachdeva said. \u201c[and] some other drugs that could be used for other autoimmune indications or cancer indications.\u201d\u00a0<\/p>\n